Ratings Biocon Limited

Equities

BIOCON

INE376G01013

Delayed NSE India S.E. Other stock markets 02:45:05 2024-05-29 am EDT			5-day change	1st Jan Change
319 ^INR	+0.41%		+3.59%	+27.78%

May. 24	INDIA STOCKS-Indian shares surrender gains as U.S. rate worries weigh	RE
May. 24	Biocon Ties Up with Handok to Market Anti-Diabetic Drug Liraglutide in South Korea	MT

Summary

According to Refinitiv, the company's ESG score for its industry is good.

Strengths

Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.

Weaknesses

The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
With an expected P/E ratio at 39.91 and 41.33 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
With an enterprise value anticipated at 3.58 times the sales for the current fiscal year, the company turns out to be overvalued.
The valuation of the company is particularly high given the cash flows generated by its activity.
The company is not the most generous with respect to shareholders' compensation.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
BIOCON LIMITED	+27.78%	4.56B	A-
VERTEX PHARMACEUTICALS INCORPORATED	+9.83%	115B	B+
REGENERON PHARMACEUTICALS, INC.	+10.80%	105B	B+
BIONTECH SE	-10.84%	22.71B	B+
ARGENX SE	-1.69%	21.83B	B
GENMAB A/S	-10.23%	18.18B	A-
WUXI APPTEC CO., LTD.	-41.92%	16.52B	A-
BEIGENE, LTD.	-15.11%	16.01B	B
NEUROCRINE BIOSCIENCES, INC.	+6.62%	14.14B	C+
SAREPTA THERAPEUTICS, INC.	+17.53%	10.71B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes